Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Metoject® Subcutaneous Injection Pen Approved in Japan for methotrexate Treatment
Details : Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Product Name : Metoject
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Metoject® Subcutaneous Injection Syringe (Methotrexate) Launched in Japan for Rheumatoid Arthritis
Details : Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan. It is approved in approximately 50 countries, primarily in Europe.
Product Name : Metoject
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
